VBI hepatitis B vaccine meets main goals in late-stage trial

By | June 17, 2019

(Reuters) – VBI Vaccines Inc said on Monday a late-stage study testing its hepatitis B vaccine met its main goals.

The trial tested VBI’s Sci-B-Vac against GlaxoSmithKline’s’s Engerix-B vaccine, which was first approved in the United States in 1989.

Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber

Reuters: Health News